Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
329actual
Sites
7
Country
Iraq
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-10 | actual | When the study began enrolling |
| Primary completion | 2025-11-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-04 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Congenital Bleeding Disorder
- Haemophilia A
Intervention
- Drug: Turoctocog alfa — also filed as NovoEight
Primary outcome
what the primary-completion date above is the date OFAnnual bleeding Rate (ABRs) among patients treated with different regimen of turoctocog alfa after previous FVIII replacement therapy
measured From baseline (first day of receiving turoctocog alpha) to month 12 after switching to turoctocog alfa
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed